Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate Safety and Efficacy of DCVAC/LuCa Added to Standard First Line ChT With Carboplatin and Paclitaxel +/- Immune Enhancers (Interferon-α and Hydroxychloroquine) vs ChT Alone in Patients With Stage IV NSCLC

NCT02470468 is registered in ClinicalTrials.gov with SOTIO a.s. as lead sponsor.

NCT NCT02470468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02470468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate Safety and Efficacy of DCVAC/LuCa Added to Standard First Line ChT With Carboplatin and Paclitaxel +/- Immune Enhancers (Interferon-α and Hydroxychloroquine) vs ChT Alone in Patients With Stage IV NSCLC
Lead sponsor
SOTIO a.s.
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2014
Completion date
November 30, 2021
Enrollment
105 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv non-small cell lung cancer